Man Group plc increased its position in shares of Catalent Inc (NYSE:CTLT) by 165.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,518 shares of the company’s stock after acquiring an additional 62,033 shares during the period. Man Group plc owned about 0.07% of Catalent worth $4,743,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in CTLT. Highline Capital Management L.P. acquired a new stake in shares of Catalent in the second quarter worth about $111,494,000. Wells Fargo & Company MN boosted its position in Catalent by 205.8% during the second quarter. Wells Fargo & Company MN now owns 1,528,009 shares of the company’s stock worth $82,833,000 after purchasing an additional 1,028,286 shares during the period. Viking Global Investors LP boosted its position in Catalent by 50.5% during the second quarter. Viking Global Investors LP now owns 1,595,579 shares of the company’s stock worth $86,496,000 after purchasing an additional 535,066 shares during the period. Nuveen Asset Management LLC bought a new stake in Catalent during the second quarter worth approximately $23,144,000. Finally, BlackRock Inc. grew its holdings in Catalent by 2.8% during the second quarter. BlackRock Inc. now owns 14,307,589 shares of the company’s stock valued at $775,615,000 after purchasing an additional 388,615 shares during the last quarter.
A number of analysts have recently weighed in on the stock. Robert W. Baird boosted their price objective on shares of Catalent from $50.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Zacks Investment Research lowered shares of Catalent from a “hold” rating to a “sell” rating in a research note on Tuesday, December 3rd. Stephens began coverage on shares of Catalent in a research note on Thursday, October 17th. They issued an “overweight” rating and a $56.00 target price on the stock. ValuEngine downgraded shares of Catalent from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Morgan Stanley boosted their target price on shares of Catalent from $50.00 to $61.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $57.86.
In other news, SVP Ricardo Pravda sold 2,612 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $52.73, for a total transaction of $137,730.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO John R. Chiminski sold 97,043 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $48.84, for a total value of $4,739,580.12. The disclosure for this sale can be found here. Insiders have sold 145,287 shares of company stock worth $7,275,066 in the last ninety days. 1.30% of the stock is currently owned by insiders.
CTLT opened at $52.05 on Monday. The company has a quick ratio of 1.65, a current ratio of 2.06 and a debt-to-equity ratio of 1.73. The stock’s 50 day moving average price is $50.40 and its two-hundred day moving average price is $51.44. The firm has a market capitalization of $7.62 billion, a P/E ratio of 30.98, a price-to-earnings-growth ratio of 2.25 and a beta of 1.68. Catalent Inc has a 12-month low of $29.23 and a 12-month high of $58.38.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.07. The company had revenue of $664.70 million during the quarter, compared to analyst estimates of $634.87 million. Catalent had a return on equity of 15.30% and a net margin of 5.77%. The company’s quarterly revenue was up 20.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.28 earnings per share. As a group, analysts anticipate that Catalent Inc will post 1.78 earnings per share for the current year.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: What is systematic risk?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.